The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).
 
Sohei Satoi
Speakers' Bureau - Taiho Pharmaceutical
 
Michiaki Unno
Honoraria - Abbvie; Asahi Kasei; Astellas Pharma; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Johnson & Johnson; Lilly; Mylan; Novartis; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Yakult Honsha (Inst)
 
Fuyuhiko Motoi
Speakers' Bureau - Taiho Pharmaceutical
 
Yutaka Matsuyama
No Relationships to Disclose
 
Ippei Matsumoto
No Relationships to Disclose
 
Suefumi Aosasa
No Relationships to Disclose
 
Hirofumi Shirakawa
No Relationships to Disclose
 
Keita Wada
No Relationships to Disclose
 
Tsutomu Fujii
Honoraria - Asahi Kasei; Chugai Pharma; Covidien/Medtronic; CSL Behring; EA Pharma; Japan Blood Products Organization; Johnson & Johnson; Kaken Pharmaceutical; Lilly; Miyarisan pharmaceutical; MSD; Novelpharm; Otsuka; Taiho Pharmaceutical; TERUMO; Tsumura & Co.
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Central Medical (Inst); Chugai Pharma (Inst); Covidien/Medtronic (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); Eisai (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Miyarisan pharmaceutical (Inst); Nihonkayaku (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TERUMO (Inst); Tsumura & Co. (Inst)
 
Hideyuki Yoshitomi
No Relationships to Disclose
 
Shinichiro Takahashi
No Relationships to Disclose
 
Masayuki Sho
No Relationships to Disclose
 
Hideki Ueno
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Baxalta (Inst); Lilly (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst)
 
Tomohisa Yamamoto
No Relationships to Disclose
 
Tomoo Kosuge
No Relationships to Disclose